Roxithromycin in the Therapy of Streptococcus Pyogenes Throat Infections
Overview
Authors
Affiliations
Roxithromycin in two dosage regimens was compared with erythromycin in the therapy of 227 patients with throat infectious due to Streptococcus pyogenes. All three groups had the same clinical efficacy but roxithromycin 300 mg daily was less effective than erythromycin 500 mg qds in eradicating S. pyogenes while there were less antibiotic-related side effects with roxithromycin 150 mg bd than with erythromycin.
Pradhan B, Lodhi L, Dey K, Ghosh M RSC Adv. 2024; 14(25):17733-17770.
PMID: 38832242 PMC: 11145140. DOI: 10.1039/d4ra00718b.
The Place of Macrolides in the Treatment of Upper Respiratory Tract Infections.
Gomez-Barreto D Drug Investig. 2020; 3(Suppl 3):17-20.
PMID: 32287508 PMC: 7103249. DOI: 10.1007/BF03258330.
The use of macrolides in respiratory tract infections.
Pechere J Int J Antimicrob Agents. 1993; 3 Suppl 1:S53-61.
PMID: 18611579 PMC: 7135373. DOI: 10.1016/0924-8579(93)90035-4.
Formulary management of macrolide antibiotics.
Guay D Pharmacoeconomics. 1995; 8(6):491-512.
PMID: 10160079 DOI: 10.2165/00019053-199508060-00005.
Scott W, Tilyard M, Dovey S, Cooper B, Scott H Pharmacoeconomics. 1993; 4(2):122-30.
PMID: 10146972 DOI: 10.2165/00019053-199304020-00006.